Review: Mechanistic target of rapamycin (mTOR) pathway, focal cortical dysplasia and epilepsy

157Citations
Citations of this article
150Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Over the last decade, there has been increasing evidence that hyperactivation of the mechanistic target of rapamycin (mTOR) pathway is a hallmark of malformations of cortical development such as focal cortical dysplasia (FCD) or hemimegalencephaly. The mTOR pathway governs protein and lipid synthesis, cell growth and proliferation as well as metabolism and autophagy. The molecular genetic aetiology of mTOR hyperactivation has only been recently clarified. This article will review the current and still evolving genetic advances in the elucidation of the molecular basis of FCD. Activating somatic mutations in the MTOR gene are to date the most frequent mutations found in FCD brain specimens.

Cite

CITATION STYLE

APA

Marsan, E., & Baulac, S. (2018, February 1). Review: Mechanistic target of rapamycin (mTOR) pathway, focal cortical dysplasia and epilepsy. Neuropathology and Applied Neurobiology. Blackwell Publishing Ltd. https://doi.org/10.1111/nan.12463

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free